Baricitinib Has Promising Clinical Trial Results for Treating RA

This study showed that in patients with RA who were previously unresponsive to biologic DMARDs, TNF inhibitors and other agents, a daily dose of 4 mg baricitinib led to clinical improvements at Week 12. This agent may prove beneficial in severe RA for whom many treatments have already been tried.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 13;374(13):1243–1252. doi: 10.1056/NEJMoa1507247.